MARY ALLEN OLSON: Open Payments
NPI 1497488779 · HERNANDO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$851 in 54 payments from 11 companies in 2025. Trend: 2023 $537 · 2024 $1,040 · 2025 $851
Food & beverage: $851
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $295 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $250 |
| Supernus Pharmaceuticals, Inc. | 6 | $105 |
| Alkermes, Inc. | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: VRAYLAR, CAPLYTA, Qelbree, ARISTADA, FANAPT, REXULTI, Auvelity, INGREZZA.
Industry payments across MS — which companies pay providers there.
